Bought growth is still growth, but this season's results show it must be labelled

Two kinds of strong quarter

Read this earnings season quickly and the sector looks uniformly healthy. Look closer and there are two different stories behind the headline numbers.

The first is growth built in-house. Madrigal's Rezdiffra posted $431.3 million in third-quarter net sales, up 50% year on year, and the company reported its first profitable quarter. Krystal's Vyjuvek brought in $127.3 million. ANI's Purified Cortrophin Gel grew 36.1% to $138.7 million, and Harmony's Wakix delivered $269 million and reiterated full-year guidance of $1.0 billion to $1.04 billion.

The second is growth that has been assembled. BioMarin reported revenue up 32% to $1.025 billion and credited it to "a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year" as well as patient demand. ANI, meanwhile, announced an offer for Egetis Therapeutics to expand the scope and scale of its Rare Disease business.

CompePharma's view is that the sector has not yet developed an honest convention for telling these stories apart. It needs one.

Acquisitions leave fingerprints on the P&L

BioMarin's release shows why this matters. The company updated its 2026 guidance to reflect order timing uncertainty and the impact of two acquired in-process R&D charges. In other words, the deal strategy that lifts the top line also moves the guidance range. The same quarter carries the benefit of a larger portfolio and the cost of buying the next pipeline asset, and the company also added a new investigational Fabry asset to its clinical portfolio.

None of this is improper. Buying revenue and buying pipeline is a legitimate way to diversify, and BioMarin's metabolic conditions segment grew 44% while skeletal conditions grew 12%. But a reader looking at a 32% growth rate cannot tell, from the headline, how much reflects commercial execution on existing products and how much reflects a transaction. That distinction determines how repeatable the number is.

ANI illustrates the other side of the same question. Cortrophin was $138.7 million of a $290.8 million quarter, close to half of revenue, and the company narrowed its total revenue guidance to $1,085 million to $1,125 million. Offering for Egetis is a way to widen the base beyond one fast-growing product. Whether it works will depend on integration and on what the company discloses about it, not on the announcement.

The strongest counter-argument

The best objection is that investors already do this analysis. Acquired revenue is footnoted, pro forma tables exist, and sophisticated holders strip out deal effects without help. Demanding more labelling, the argument goes, adds reporting burden with little benefit, and punishes companies that choose M&A over slower organic paths.

There is something to that. But the objection assumes the reader is a specialist with time to reconcile filings. The audience for a results release also includes partners, prospective hires, licensors and counterparties, who take the headline at face value. And the organic comparison is exactly what the picture needs. Charles River reported organic revenue growth of 4.7%, a return to organic growth for the second consecutive quarter, and used the word "organic" because it carries information. A 4.7% organic number and a 32% reported number are different statements, and both are useful when each is labelled.

Why it matters now

The built-growth stories are strong but exposed to calendars of their own. Harmony cites exclusivity to March 2030 and is changing CEOs at the start of 2027. Madrigal's next outcomes data are expected in late 2027. Companies in this position will increasingly turn to acquisitions to extend their runway, as BioMarin and ANI are doing. That makes the next few reporting seasons more deal-heavy, and the labelling question more pressing.